Advances in traditional Chinese medicine treatment of non-alcoholic fatty liver disease via farnesoid X receptor.
10.19540/j.cnki.cjcmm.20230809.701
- Author:
Huan-Huan ZHAO
1
;
Ji CUI
1
;
Jin-Jia ZHANG
1
;
Jia-Xin CHEN
1
;
An-Hua SHI
1
;
Xiao-Song ZHU
1
Author Information
1. College of Basic Medicine, Yunnan University of Chinese Medicine Kunming 650500, China Key Laboratory of Microcosmic Syndrome Differentiation for Traditional Chinese Medicine Syndromes in Universities of Yunnan Province Kunming 650500, China.
- Publication Type:Journal Article
- Keywords:
farnesoid X receptor;
non-alcoholic fatty liver disease;
research progress;
traditional Chinese medicine
- MeSH:
Humans;
Non-alcoholic Fatty Liver Disease/metabolism*;
Liver;
Medicine, Chinese Traditional/adverse effects*;
Receptors, Cytoplasmic and Nuclear/metabolism*
- From:
China Journal of Chinese Materia Medica
2023;48(24):6582-6591
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease(NAFLD) is a chronic metabolic condition with rapidly increasing incidence, becoming a public health issue of worldwide concern. Studies have shown that farnesoid X receptor(FXR)-based modulation of downstream targets can improve liver function and metabolic status in the patients with NAFLD and may be a potential drug target for treating this di-sease. Great progress has been achieved in the development of drugs targeting FXR for the treatment of NAFLD. A number of studies have explored the traditional Chinese medicine and their active ingredients for the treatment of NAFLD via FXR considering the high safety and efficacy and mild side effects. This paper systematically describes the mechanism of traditional Chinese medicines in the treatment of NAFLD via FXR and the downstream targets, aiming to provide precise targets for the drug development and clinical treatment of NAFLD.
